The effects of cisplatin resistance on adenocarcinoma and lung squamous carcinoma cell growth through HDAC1 induced cell cycle

Background: Long term cisplatin is active in highly cisplatin-resistant cancer cells; however, there is little evidence for its resistant activity in lung cancer with cisplatin. Many mechanisms of cisplatin resistance have been proposed. Aims: The mechanisms of the long term of cisplatin-resistant lung cancer for histone deacetylase 1 (HDAC1) activity is unknown. The long term of cisplatin was used to analyze cisplatin-resistant non-small cell lung cancer (NSCLC) cancer cell growth. Methods: Western blot was used to analyze cell cycle-related proteins at 24 h and 48 h. Cancer cell viability was measured with MTT assay. HDAC1 transfected NSCLC cells were used to analyze the direct binding between cytosol and nucleus distribution. Here, using cell viability and migration methods we firstly found cisplatin-resistant NSCLC cells growth by targeting HDAC1 at 24 h and 48 h. Expression of cisplatin was negatively correlated with HDAC1. And HDAC1 inhibitor, VPA, in the NSCLC cancer cells were predicted. Results: Further experiments confirmed that HDAC1 directly targeted E2F and cisplatin at 24 h. Besides, HDAC1 and cisplatin inhibited NSCLC cell growth and reduced expression of E2F and Cyclin E proteins at 48 h. The long-term compromised cisplatin-induced E2F suppression and cancer cell growth. NSCLC cancer cells co-transfected with HDAC1 had a higher cell cycle proliferation at 24 h. Conclusion: Taken all together, cisplatin interferes with DNA replication kills the cancer cell proliferation; however, long term increased toxification invalid effects of cisplatin, inhibition of apoptosis and DNA repair, induced cisplatin resistance.